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PREVENTING NEONATAL ABSTINENCE
SYNDROME WITHIN THE
OPIOID EPIDEMIC:
A UNIFORM FACILITATIVE POLICY
JEREMIAH A. HO* AND ALEXANDER O. ROVZAR**
ABSTRACT
The United States is currently in the midst of an opioid epidemic that has
hit states in southern New England particularly hard—with Massachusetts as
one primary example. One of the many unfortunate consequences of the epi-
demic is a dramatic upsurge in cases of opioid use disorder by pregnant women,
often resulting in children born with neonatal abstinence syndrome. Neonatal
abstinence syndrome is a clinical syndrome that occurs when a newborn suffers
withdrawal symptoms as a consequence of abrupt discontinuation of prenatal
substance exposure. The expenses of treating, monitoring, and rehabilitating
these chemically-dependent newborns are predominantly shouldered by state
taxpayers and are extremely costly, with a mean cost per stay exceeding $90,000
for pharmacologically-treated cases.
This Article illustrates a policy, grounded in facilitative principles, de-
signed to reduce the rate of neonatal abstinence syndrome in the Commonwealth
of Massachusetts. Early identification of opioid misuse during pregnancy is the
threshold requirement of the proposed solution’s success. Another key compo-
nent of the policy necessitates implementation of a standardized protocol to be
adhered to uniformly throughout public hospitals statewide. The Article con-
cludes by reemphasizing the importance of acting promptly and assertively to
protect society’s most vulnerable members from the opioid epidemic.
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I. INTRODUCTION
The threat of narcotics . . . properly frightens many Americans. It
comes quietly into homes and destroys children, it moves into
neighborhoods and breaks the fiber of community which makes
neighbors. It is a problem which demands compassion, and not
simply condemnation . . . We must try to better understand the
confusion and disillusion and despair that bring people . . . to the
use of narcotics and dangerous drugs.1
To baby boomers, it may seem surreal that nearly fifty years have
passed since President Nixon declared war on drugs, identifying drug abuse
(hereinafter referred to as “substance use disorder” and/or “substance mis-
use”)2 in America as “public enemy number one.”3 On a similar note, and
perhaps etched in the early memories of those who came of age in the 1980s,
President and Mrs. Reagan addressed the nation in 1986, calling for a “na-
tional crusade” against the “cancer of drugs.”4 Today, the perpetual war on
illegal substances rages on, with rates of misuse continuing to soar and over-
doses reaching all-time highs.5
1 See Richard Nixon, Special Message to the Congress on Drug Abuse Prevention and
Control, THE AMERICAN PRESIDENCY PROJECT (June 17, 1971), http://www.presidency.ucsb
.edu/ws/?pid=3048 [https://perma.cc/P27X-WJ7T].
2 As part of an initiative to reduce stigma and support treatment for substance use disor-
ders, the American Medical Association, the American Society of Addiction Medicine, and
other professional associations have urged the adoption of clinical, non-stigmatizing language
in connection with communications relative to substance misuse. See, e.g., OFFICE OF NAT’L
DRUG CONTROL POL’Y, CHANGING THE LANGUAGE OF ADDICTION (Oct. 4, 2016), https://www
.whitehouse.gov/ondcp/changing-the-language-draft [https://perma.cc/R7HF-XND4].
3 Richard Nixon, Remarks about an Intensified Program for Drug Abuse Prevention and
Control, THE AMERICAN PRESIDENCY PROJECT (June 17, 1971), http://www.presidency.ucsb
.edu/ws/?pid=3047 [https://perma.cc/XVN6-HN8N].
4 Gerald M. Boyd, Reagans Advocate ‘Crusade’ on Drugs, N.Y. TIMES (Sept. 15, 1986),
http://www.nytimes.com/1986/09/15/us/reagans-advocate-crusade-on drugs.html [https://per
ma.cc/6PHW-5NSS].
5 An estimated 24.6 million Americans 12 years or older (9.4 percent of the population)
are living with substance dependence as of 2013. See SUBSTANCE ABUSE & MENTAL HEALTH
SERV. ADMIN., U.S. DEP’T OF HEALTH & HUMAN SERVS., Pub. No. 14-4863, NAT’L SURV. ON
DRUG USE & HEALTH 3 (2014); see also Nadia Kounang, Drug Overdose Deaths Reach All-
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Perhaps more alarming than the high number of Americans living with
substance use disorders is the phenomenal convergence of two major
forces—potent heroin and liberally prescribed pain medication. Each com-
plements the other in forming a multi-dimensional enemy, more threatening
than any that the Nixon or Reagan administration could have imagined. As
opioid misuse reaches catastrophic levels, federal and state governments
must do battle on two separate fronts by encouraging safer prescription prac-
tices in the health care profession and stopping the flood of pure and deadly
heroin heading towards our most afflicted areas.6 Consequently, our nation is
in the midst of a perfect storm,7 and the war envisioned by the Nixon and
Reagan administrations has evolved into a plague—a problem that has be-
come known as America’s opioid epidemic.8
On March 27, 2014, during his final year as governor of Massachusetts,
Deval Patrick declared a public health emergency in the Commonwealth in
response to the growing opioid epidemic.9 The governor instructed the Mas-
sachusetts Department of Public Health (“DPH”) to implement a strategy to
combat overdoses, to stem the tide of the opioid epidemic, to guide misusers
toward recovery, and to devise a long-term solution to substantially reduce
opioid misuse in Massachusetts.10 In accordance with Governor Patrick’s or-
der, DPH created an Opioid Task Force, which was given a sixty-day win-
dow to explore the heart of the issue and to provide DPH with
recommendations to contain the epidemic.11 The Task Force highlighted as a
paramount concern the urgent necessity to regulate opioid prescribing prac-
time High, CNN.COM (Dec. 18, 2015), http://www.cnn.com/2015/12/18/health/drug-overdose-
deaths-2014/ [https://perma.cc/3WXZ-8B5S].
6 See Daniel J. McGraw, How Big Pharma Gave America Its Heroin Problem, PACIFIC
STANDARD (Nov. 30, 2015), http://www.psmag.com/health-and-behavior/how-big-pharma-
gave-america-its-heroin-problem [https://perma.cc/77F9-SEMY] (“What followed was not all
that surprising. Many grew addicted to the opioids, and when the prescriptions ran out, they
turned to heroin because of its availability and relatively low cost. The Mexican drug cartels
saw this trend and promptly began growing their opium plants, which they consciously made
purer and less expensive. And those cartels targeted the suburbs, where those introductory
OxyContin prescriptions were being filled—and where the money was.”).
7 A perfect storm occurs when a critical or disastrous situation is created by a powerful
concurrence of factors. Perfect Storm, MERRIAM-WEBSTER DICTIONARY, http://www.merriam-
webster.com/dictionary/perfect%20storm [https://perma.cc/Q2AK-5VMX] (last visited Feb.
1, 2016).
8 Daniel Sosin, Examining the Growing Problems of Prescription Drug and Heroin
Abuse, CTRS. FOR DISEASE CONTROL & PREVENTION (Apr. 29, 2014), http://www.cdc.gov/
washington/testimony/2014/t20140429.htm [https://perma.cc/VJS2-BBYT].
9 In 2014, there were an estimated 1,256 opioid-related deaths in Massachusetts. This
figure is nearly four times the 338 opioid-related deaths recorded in the year 2000. MA DEP’T
PUB. HEALTH, DATA BRIEF: FATAL OPIOID-RELATED OVERDOSES AMONG MASSACHUSETTS RE-
SIDENTS (Aug. 2015), http://www.mass.gov/eohhs/docs/dph/quality/drugcontrol/county-level-
pmp/data-brief-aug-2015-overdose-county.pdf [https://perma.cc/A2RW-EF5K].
10 MA DEP’T OF PUB. HEALTH, FINDINGS OF THE OPIOID TASK FORCE AND DEP’T OF PUB.
HEALTH RECOMMENDATIONS ON PRIORITIES FOR INVESTMENTS IN PREVENTION, INTERVENTION,
TREATMENT AND RECOVERY 1 (June 10, 2014), http://www.mass.gov/eohhs/docs/dph/sub-
stance-abuse/opioid /report-of-the-opioid-task-force-6-10-14.pdf [https://perma.cc/7FP5-
V65P].
11 Id. at 4.
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tices.12 The Task Force also listed crucial steps toward combating the prob-
lem,13 including increased education on the dangers of opioid use,14
centralized treatment resources improving accessibility,15 and a statewide ex-
pansion of recovery services.16
Governor Patrick’s term ended on January 8, 2015.17 His successor, cur-
rent Massachusetts Governor Charlie Baker, immediately made the opioid
crisis a focal point of his administration, revealing new plans to curb the
epidemic’s momentum shortly after his inauguration.18 In February of 2015,
Governor Baker announced that Massachusetts Health and Human Services
Secretary Marylou Sudders and Attorney General Maura Healey would lead
a panel charged with actively collaborating with substance use disorder ex-
perts, prescribers, and members of the community to devise “specific,
targeted and tangible recommendations to increase public awareness about
[opioids] and reduce the rate of addiction.”19 Three months later, the panel
presented the Governor with a detailed report, containing sixty-five steps to
eradicate the deadly opioid epidemic.20 Unfortunately, as Massachusetts re-
sidents continue to succumb to opioid use disorder at notable rates,21 the
multi-faceted plan will not be implemented as quickly as devised, further
delaying its impact.22
12 Id. at 11–12.
13 Id. at 17.
14 Id. at 9.
15 Id. at 12–13.
16 Id. at 15–17.
17 See Michael Levenson, ‘Lone Walk’ Leads Deval Patrick Back to Private Life, BOS.
GLOBE (Jan. 7, 2015), https://www.bostonglobe.com/news/politics/ 2015/01/07/patrick/
A2kpDxeZDjSkyNeM8JM0fK/story.html [https://perma.cc/NJX5-R4RZ].
18 See Felice J. Freyer, Governor Announces New Panel on Opioids, BOS. GLOBE (Feb. 19,
2015), https://www.bostonglobe.com/metro/2015/02/19/governor-charlie-baker-establishes-
panel-address-opioid-crisis/WSfp7DYr9q52 OZSvhZaumM/story.html [https://perma.cc/
FNH7-ESZ3] (reporting on Governor Baker’s appointment of a sixteen-member working
group to hold public meetings, assess resources devoted to the problem, and provide a specific
plan to tackle the epidemic by May 2015).
19 MA Governor Baker Announces Initial Steps to Combat Opioid Addiction Crisis,
WORKCOMPWIRE.COM (Feb. 26, 2015), http://www.workcompwire.com/2015/02/ma-governor-
baker-announces-initial-steps-to-combat-opioid-addiction-crisis/ [https://perma.cc/C3WB-3N
Q2].
20 MA DEP’T PUB. HEALTH, RECOMMENDATIONS OF THE GOVERNOR’S OPIOID WORKING
GROUP 2 (June 11, 2015).
21 In 2014, the estimated rate of unintentional opioid-related overdose deaths, which in-
cludes deaths related to heroin, reached levels previously unseen. DATA BRIEF: FATAL OPIOID-
RELATED OVERDOSES AMONG MASSACHUSETTS RESIDENTS, supra note 9. The estimated rate of
18.6 deaths per 100,000 residents for 2014 is the highest ever for unintentional opioid over-
doses and represents a 251% increase from the rate of 5.3 deaths per 100,000 residents in
2000. Id.
22 The findings by the panel include short and long term action items to be implemented
between now and the next three years, some requiring legislative action and funding, while
others will be achieved through partnerships with private industry and federal leaders. See
PRESS RELEASE, THE OFFICIAL WEBSITE OF THE GOVERNOR OF MA, Governor Baker Releases
Opioid Working Group Recommendations (June 22, 2015), http://www.mass.gov/governor/
press-office/press-releases/fy2015/governor-releases-opioid-working-group-recommendations
.html [https://perma.cc/RF6X-W7K5].
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The magnitude of the opioid crisis has reached epidemic proportions.23
As illustrated by the findings of the Task Force during the Patrick adminis-
tration and the recent formulation of Governor Baker’s sixty-five step plan,
the issue presents many challenges, each requiring substantial reform.24 This
Article highlights the dramatic rise in reported cases of neonatal abstinence
syndrome (NAS)25 and considers potential ways forward for reform. Part II
of the Article briefly defines NAS, traces its historical co-existence with
opioid misuse, and emphasizes the gravity of social and economic burdens
posed by the spike in NAS rates—a troubling consequence of the ongoing
opioid epidemic. Part III acknowledges the successes of the two opioid ago-
nist26 medications generally approved to treat opioid dependence during
pregnancy, while exposing the unfortunate reality that these medications
also contribute to increased incidence of NAS. Part IV discusses OxyContin
and its role in the opioid epidemic and the resulting elevation in NAS rates.
Part V summarizes recent and ongoing efforts to contain the epidemic on
federal and state levels, and suggests that the current state of affairs in the
Commonwealth requires immediate and aggressive legislative action. Fi-
nally, Part VI illustrates a facilitative policy—one that assumes government
and pregnant misusers share an interest in promoting fetal health—that is
designed to reduce rates of NAS. The system’s success relies on early identi-
fication of opioid misuse during pregnancy, as well as adherence to a stan-
dardized protocol implemented uniformly throughout public hospitals in
Massachusetts. The Article concludes by reemphasizing the importance of
acting promptly and aggressively in order to protect society’s most vulnera-
ble members from this deadly epidemic.
23 See DATA BRIEF: FATAL OPIOID-RELATED OVERDOSES AMONG MASSACHUSETTS RE-
SIDENTS, supra note 9.
24 See RECOMMENDATIONS OF THE GOVERNOR’S OPIOID WORKING GROUP, supra note 20,
at 2 (recommending bold new strategies and strong partnerships among medical community,
law enforcement, the judiciary, insurers, providers, health and human services agencies,
elected officials and the public); see also Governor Baker Releases Opioid Working Group
Recommendations, supra note 22 (“The solution requires a strong public health approach fo-
cusing on prevention, intervention, treatment and recovery.”).
25 See Michael Levenson, More Than 1,700 Born in Mass. with Drug Issues in 2014, BOS.
GLOBE (Mar. 20, 2015), https://www.bostonglobe.com/metro/2015/03/19/with-scourge-opia
tes-more-babies-mass-born-with-addiction/bz75a0bf5zmxDogZFuAuQO/story.html [https://
perma.cc/ANM6-PFQA] (reporting that more than 1,700 infants born in 2014 were exposed to
drugs and that Boston Medical Center treats triple the number of substance-exposed infants as
it did five to ten years ago).
26 An agonist is a chemical substance (i.e., a drug) capable of combining with a receptor
on a cell and initiating the same reaction or activity typically produced by the binding of an
endogenous substance. Agonist, MEDLINE PLUS ONLINE DICTIONARY, http://c.merriam-webster
.com/medlineplus/agonist [https://perma.cc/C472-QFGM] (last visited Feb. 1, 2016).
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II. NEONATAL ABSTINENCE SYNDROME
A. Symptoms in Newborns
Months before her birth on April 11, 2011, Mya Barry was in grave
danger.27 Shortly after Mya’s pregnant mother, a daily heroin user, had given
birth to Mya, the opioid-dependent infant went into withdrawal.28 Mya spent
six weeks in the hospital while doctors treated her with a morphine-based
weaning protocol to ease her sickness and pain while she detoxified from
opioids.29 After her hospital stay, Mya was released to her family.30 Within
five months, local police officers found Mya, cold and blue, lying on her
grandmother’s living room floor.31 Mya died from ingesting her mother’s her-
oin-tainted breast milk.32 Mya Barry is one of thousands who have fallen
victim to the deadly epidemic—tragically contributing another notch to its
belt.33
Although the heroin that passed in utero was not the direct cause of
Mya Barry’s death, such prenatal drug exposure, the result of which is ex-
treme discomfort to the newborn, has become increasingly common as the
opioid epidemic continues its merciless sweep.34 The condition, known as
neonatal abstinence syndrome (NAS), increased five-fold nationwide be-
tween 2000 and 2012.35 In Massachusetts, where the opioid epidemic has hit
especially hard, data and reports suggest that the rate of opioid-dependent
newborns is two to three times the national average.36 Although more preva-
lent today, the social concern is by no means a new phenomenon, as NAS
has paralleled trends of opioid use dating back to the mid-nineteenth
century.37
NAS is a clinical syndrome that occurs when a newborn suffers with-
drawal symptoms as a consequence of an abrupt discontinuation of exposure
27 See Jennifer McKim & Michael Bottari, Cases of newborns with addictions soaring,
BOS. GLOBE (Mar. 30, 2014), https://www.bostonglobe.com/metro/2014/03/29/explosion-
drug-exposed-infants-reveals-weakness-massachusetts-child-protection/0ZhSZUhIBbn0jVEl
OBgIsJ/story.html [https://perma.cc/2KCH-VMSZ].
28 Id.
29 Id.
30 Id.
31 Id.
32 Id.
33 DATA BRIEF: FATAL OPIOID-RELATED OVERDOSES AMONG MASSACHUSETTS RESIDENTS,
supra note 9.
34 See Levenson, supra note 25.
35 See Gary Peltz & Kanwaljeet J. S. Anand, Long-Acting Opioids for Treating Neonatal
Abstinence Syndrome: A High Price for a Short Stay?, 314 J. AM. MED. ASS’N 2023, 2023
(2015).
36 See Felice J. Freyer, Hospitals Adapt as Opioid Epidemic Hits Infant Victims, BOS.
GLOBE (June 28, 2015), https://www.bostonglobe.com/metro/2015/06/27/rise-drug-dependent-
babies-challenges-doctors-families-social-services/wUDg5j1UInpDckTX6c5XEP/story.html
[https://perma.cc/3BDE-X4G9].
37 See infra notes 47–62 and accompanying text (explaining historical records of NAS in
America).
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to addictive substances.38 Common symptoms of NAS are tremors, high-
pitched cries, sneezing, vomiting, diarrhea, sweating, and fever.39 The medi-
cal field recognizes two types of NAS: (1) NAS resulting from prenatal ex-
posure to addictive substances in utero, and (2) NAS due to postnatal
discontinuation of opioid painkillers.40 The recent surge in NAS diagnoses in
newborns is attributable to maternal opioid dependence.41 Such prenatal ex-
posure is the focus of this Article.
B. Historical Emergence
During the Civil War, morphine was plentifully dispensed to sick and
wounded soldiers, leaving many dependent on opioids.42 Hence, this first
major wave of opioid misuse appropriately earned itself the sobriquet “the
soldier’s disease.”43 Living up to its reputation as a disease that does not
discriminate,44 substance use disorder likewise skyrocketed among American
women due to the widespread availability of opioids, which were openly
sold in drug stores without the need for a prescription.45 In fact, by the begin-
ning of the twentieth century, due in large part to the liberal prescription of
opioids to treat pain and discomfort, opioid misusers who were female likely
outnumbered male counterparts.46
One year after heroin was first synthesized in 1875 and was advertised
as a “non-addictive” alternative to morphine, a doctor anonymously re-
38 See Kimberly G. Lee, Neonatal Abstinence Syndrome, MEDLINEPLUS MED. ENCYC.,
https://www.nlm.nih.gov/medlineplus/ency/article/007313.htm [https://perma.cc/84J8-HX28]
(last updated Nov. 14, 2013).
39 Walter K. Kraft & John N. van den Anker, Pharmacologic Management of the Opioid
Neonatal Abstinence Syndrome, 59 PEDIATRIC CLINICS N. AM. 1147, 1148 (2012).
40 Ashraf H. Hamdan, Neonatal Abstinence Syndrome, MEDSCAPE REFERENCE: DRUGS,
DISEASES & PROCEDURES, http://emedicine.medscape.com/article/978763-overview#a4
[https://perma.cc/Z255-FUM3] (last updated Nov. 27, 2016).
41 See Levenson, supra note 25.
42 See Walter Ling & Peggy Compton, Recent Advances in the Treatment of Opiate Addic-
tion, 5 CLINICAL NEUROSCIENCE RESEARCH 161 (2005), http://www.csam-asam.org/sites/de-
fault/files/pdf/misc/Ling_-_recent_.pdf [https://perma.cc/LUA6-XAG5].
43 See id.
44 See NARCOTICS ANONYMOUS WORLD SERVS. INC., NARCOTICS ANONYMOUS xviii (6th
ed. 2008) (“Addiction is a disease that does not discriminate . . . .”); see also Regardless of
Age . . . , 18 NA WAY MAG.  1, 1 (2001) (“[A]ddiction does not discriminate or attack one
branch of the population over another.”).
45 See Stephen R. Kandall, Women and Addiction in the United States—1850 to 1920,
DRUG ADDICTION RESEARCH AND THE HEALTH OF WOMEN 33, 35–36 (C.L. Wetherington &
A.B. Roman eds., 1998) http://archives.drugabuse.gov/pdf/DARHW/033-052_Kandall.pdf
[https://perma.cc/A776-ZEVM].
46 See id. Despite many epidemiologic limitations, an 1878 study found that women made
up 56 percent of 630 opium users, and 66 percent of morphine users identified in the state of
Michigan. Id. The same study revealed that the majority of misusers in 88 of the 96 towns that
reported substance use disorder were women. Id. This study, and others like it, indicate that
approximately 100,000 of the estimated 150,000–200,000 Americans with substance use disor-
der in the late 19th century were women. Id.
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ported the first case of congenital morphinism47—a complex disorder later
retitled NAS.48 A number of similar cases followed in the remaining years of
the nineteenth century, most of which resulted in newborn fatalities.49 In
April 1903, the first successful treatment of a NAS case was recorded in the
Journal of American Medicine.50 The journal article describes a baby, born to
a morphine-dependent mother, who appeared normal at birth, but began cry-
ing incessantly on the second day.51 To ease the infant’s discomfort, the doc-
tor administered small doses of morphine every other day, alleviating the
newborn’s withdrawal symptoms.52 This seminal case represents the first re-
ported successful pharmacological treatment of congenital morphism.53
Cases of NAS were reported sporadically through the early 1900s, cul-
minating in an extensive 1934 review of the disorder that cited fifty-three
U.S. cases.54 Shortly thereafter, Diseases of the Newborn, a textbook on pe-
diatrics published in 1937, officially recognized congenital morphism as a
cause of convulsions in newborns.55 Pharmacological treatment, primarily
through doctor-administered morphine, continued to serve as the primary
means of weaning dependent infants off opioids.56 A particularly severe
case, reported in 1941, deviated from the standard morphine-based treat-
ment.57 In this case, a newborn plagued by withdrawal symptoms from the
mother’s misuse of heroin was sedated with phenobarbital.58 Almost immedi-
ately, the vomiting and diarrhea subsided and the newborn began to gain
weight.59 The baby underwent regular phenobarbital treatment for eight
weeks before the dosage was tapered and eventually stopped.60 Subsequent
observations conducted over the next year indicated normal childhood devel-
opment.61 From this point, phenobarbital sedation became a recognized ther-
47 Meyer A. Perlstein, Congenital Morphinism: A Rare Cause of Convulsions in the New-
born, 135 J. AM. MED. ASS’N 633, 633 (1947).
48 Prabhakar Kocherlakota, Neonatal Abstinence Syndrome, 134 PEDIATRICS e547, e548
(2014).
49 See Perlstein, supra note 47, at 633 (reporting 12 infants born to drug addicted mothers
in 1892, nine of whom died).
50 Id.
51 See id.
52 See id.
53 See Kocherlakota, supra note 48, at e548.
54 See Perlstein, supra note 47, at 633 (citing 50 cases of congenital morphinism in Ger-
man journals and 53 in American literature).
55 See id. In his 1937 textbook on pediatrics, Diseases of the Newborn, Tow describes
thirteen cases of infants born into opiate withdrawal, six of which died in spite of treatment.
See generally ABRAHAM TOW, DISEASES OF THE NEWBORN 395 (1937).
56 See Perlstein, supra note 47, at 633.
57 See id.
58 The newborn vomited excessively and suffered from diarrhea, tremors, and occasional
seizures—all common symptoms of NAS. See id.
59 See id.
60 See id.
61 See id.
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apeutic agent for NAS, often accompanying full agonists such as morphine
or methadone.62
C. Contemporary Societal Costs
Until recently, the societal and economic damage caused by NAS has
been difficult to accurately assess due in part to limited self-reporting of
substance misuse and underreporting by national and state surveyors.63 How-
ever, a combination of forces over the years, most notably the increase in
overall opioid use disorder rates in connection with the ongoing crisis, has
uncovered an alarmingly high number of NAS cases, forcing federal and
state agencies to take note.64 The wide assortment and availability of sub-
stances such as methadone, buprenorphine, prescription opioid analgesics,
anti-depressants, and anxiolytics have increased the complexity and preva-
lence of NAS.65 With these new medications in play, and a full-blown epi-
demic of prescription pill and heroin misuse sweeping across the nation, the
number of newborns requiring hospitalization and treatment for opioid with-
drawal is unprecedented.66
Aside from the clear public health issues that arise from the soaring
number of babies born substance-dependent, expenses for hospital stays and
treatment associated with NAS are predominantly shouldered by state tax-
payers and have reached extraordinary levels.67 An estimated 13,500 babies
are born substance-dependent in the United States each year due to in utero
62 See id.; see also Kocherlakota, supra note 48, at e554.
63 See Kraft & van den Anker, supra note 39, at 1148.
64 See Sosin, supra note 8 (noting a quadrupling of opioid pain reliever overdoses between
1999 and 2010, the CDC declared the problem of prescription drug abuse a public health
epidemic); MA DEP’T PUB. HEALTH, DATA BRIEF: FATAL OPIOID-RELATED OVERDOSES AMONG
MASSACHUSETTS RESIDENTS, supra note 9; see also Freyer, Hospitals Adapt as Opioid Epi-
demic Hits Infant Victims, supra note 36 (acknowledging that babies withdrawing from drugs
used to be a rare occurrence confined to inner cities, but today, throughout the Common-
wealth, they are a regular presence as the “opioid epidemic cascades down to the next
generation”).
65 See Kocherlakota, supra note 48, at e549 (explaining that NAS has become more com-
mon and more complex “not only because of an increase in the use of opioids, but also be-
cause of the simultaneous use of multiple opioids”).
66 “Approximately 13,500 neonates born in the United States each year develop NAS, and
this number has increased nearly [five]-fold between 2000 and 2012.” Peltz & Anand, supra
note 35, at 2023.
67 See J.C. Monahan, Cape Facing Epidemic of Drug-Addicted Newborns, WCVB.COM
(Nov. 14, 2013) http://www.wcvb.com/article/cape-facing-epidemic-of-drug-addicted-
newborns/8191295. [https://perma.cc/VS3N-FLNC] (referring to a 44 percent increase of ba-
bies born with NAS at Cape Cod Hospital between 2011 and 2012, the cost of which falls on
Massachusetts taxpayers); see also Dramatic Increases in Maternal Opioid Use and Neonatal
Abstinence Syndrome, NAT’L INST. ON DRUG ABUSE, https://www.drugabuse.gov/related-top-
ics/trends-statistics/infographics/dramatic-increases-in-maternal-opioid-use-neonatal-absti-
nence-syndrome [https://perma.cc/3UAS-T6ZQ] (last updated Sept. 2015) (estimating NAS is
costing hospitals approximately $1.5 billion, 81 percent of which was paid by state Medicaid
programs).
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exposure to addictive chemicals.68 The average hospital stay for a baby with-
drawing from opioids is about sixteen days, with a mean cost per stay of
$93,400 for pharmacologically treated cases.69 A 2015 nationwide study
conducted by the Journal of Perinatology estimated that NAS-related hospi-
tal stays cost $1.5 billion per year, eighty percent of which is paid by state
Medicaid programs.70 Hit particularly hard by the national opioid crisis,
Massachusetts absorbs more than its share of these costs.71 Between March
1, 2014, and March 31, 2015, the Massachusetts Department of Children and
Families responded to 2,265 cases of NAS in the Commonwealth.72 This
thirteen-month span alone proved tremendously costly to Massachusetts’ tax-
payers, costing them approximately $169 million.73 The opioid epidemic
continues to victimize citizens at record high rates, and despite recent pro-
gress by the Baker administration, does not appear to be waning.74
III. THE BEGINNINGS OF OPIOID MISUSE TREATMENT
Scientific and medical advances over the last few decades have ended
the debate over whether substance use disorder is a disease or a moral
choice.75 Research has proven that the disorder is a brain disease that affects
an individual’s behavior.76 The disease can be effectively treated and man-
aged, usually requiring a detoxification period, substantial counseling, and
often times, pharmacological treatment.77 Medication is a key component in
treating opioid misuse, and in conjunction with adequate behavioral therapy,
can guide substance misusers toward full recovery.78
Long-term opioid misuse desensitizes the brain’s opiate receptors to en-
dorphins, hormonal groups naturally produced by the body to endure pain or
68 See Peltz & Anand, supra note 35, at 2023.
69 See Katie Lannan, New Program in Massachusetts for Newborns Exposed to Drugs,
STATE HOUSE NEWS SERV. (Dec. 24, 2015), http://www.telegram.com/article/20151224/
NEWS/151229446 [https://perma.cc/F45U-TCKP] ; see also Freyer, Hospitals Adapt as
Opioid Epidemic Hits Infant Victims, supra note 36 (stating the average hospital stay for a
baby withdrawing from drugs is sixteen days).
70 Freyer, Hospitals Adapt as Opioid Epidemic Hits Infant Victims, supra note 36.
71 Id.
72 Id.
73 Multiplying $93,400 (the average cost for a pharmacologically treated NAS case) by
2,265, (cases of children exposed to drugs over the thirteen-month period) yields a product of
$211,551,000. 80% of this figure is $169,240,800. See id.
74 DATA BRIEF: FATAL OPIOID-RELATED OVERDOSES AMONG MASSACHUSETTS RESIDENTS,
supra note 9.
75 See Alan I. Leshner, Addiction Is a Brain Disease, 17 ISSUES IN SCI. AND TECH., no. 3
(2001) (defining addiction as a brain disease expressed in the form of compulsive behavior).
76 See NAT’L INST. ON DRUG ABUSE, U.S. DEP’T OF HEALTH & HUMAN SERVICES, PRE-
SCRIPTION DRUGS: ABUSE AND ADDICTION 11 (April 2001) (“Years of research have shown
that addiction to any drug, illicit or prescribed, is a brain disease that can . . . be effectively
treated.”).
77 See id.
78 See id.
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extreme physical exertion.79 Opioid agonist medications, which activate the
same receptors as heroin, morphine, and endorphins, alleviate withdrawal
symptoms and reduce opioid cravings.80
There are currently two nationally approved opioid agonist medications
commonly prescribed to treat opioid dependence during pregnancy: metha-
done and buprenorphine.81 Although other medications are available, there is
clear consensus that these medications are the most effective means of treat-
ment for opioid misuse.82 Notwithstanding their utility in treating opioid use
disorder, methadone and buprenorphine are synthetic opioids with many of
the same properties as heroin, oxycodone, hydrocodone, and other opiate
derivatives.83 Thus, despite the advantages and benefits provided by medica-
tion-assisted therapy (MAT), newborns continue to display withdrawal
symptoms from in utero exposure to methadone, and, albeit to a lesser de-
gree, buprenorphine.84 With opioid misuse reaching ever-increasing levels,
and MAT more common and complex than ever before, NAS rates have
increased exponentially, causing serious social and economic damage.85
79 See NAT’L INST. ON DRUG ABUSE, U.S. DEP’T OF HEALTH AND HUMAN SERVICES, PRIN-
CIPLES OF DRUG ABUSE TREATMENT FOR CRIMINAL JUSTICE POPULATIONS 24, http://www.dru-
gabuse.gov/publications/principles-drug-abuse-treatment-criminal-justice-populations/what-
role-medications-in-treating-substance-abusing [https://perma.cc/4F7Y-YMBX] (last updated
April 2014); see also Endorphin, MERRIAM-WEBSTER DICTIONARY, http://www.merriam-web-
ster.com/dictionary/endorphin [https://perma.cc/EVF4-ASYQ] (last visited Feb. 1, 2016).
80 See PRINCIPLES OF DRUG ABUSE TREATMENT FOR CRIMINAL JUSTICE POPULATIONS,
supra note 79 at 24. R
81 National guidelines from the American College of Obstetricians and Gynecologists
(ACOG) and the Substance Abuse and Mental Health Services Administration (SAMSHA)
and international guidelines from the World Health Organization recommend that pregnant
women be treated with methadone or buprenorphine. See SHANNON HERTZ, FOOD AND DRUG
ADMIN. CTR. FOR DRUG EVALUATION AND RES., FDA BRIEFING DOCUMENT: RISK COMMUNI-
CATION ADVISORY MEETING 17 (2015), http://www.fda.gov/downloads/AdvisoryCommittees/
CommitteesMeetingMaterials/RiskCommunicationAdvisoryCommittee/UCM449600.pdf
[https://perma.cc/9WHN-WA8V]; SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN.,
U.S. DEP’T OF HEALTH & HUMAN SERV., THE N-SSATS REPORT: TRENDS IN THE USE OF
METHADONE AND BUPRENORPHINE AT SUBSTANCE ABUSE TREATMENT FACILITIES: 2003 TO
2011 1 (2013).
82 See Marjorie Meyer & Julie Phillips, Caring for Pregnant Opioid Abusers in Vermont:
A Potential Model for Non-urban Areas, 80 PREVENTIVE MED. 18, 18 (2015).
83 See Elinore F. McCance-Katz et al., Drug Interactions of Clinical Importance among
the Opioids, Methadone and Buprenorphine, and other Frequently Prescribed Medications: A
Review, 19(1) AM. J. ADDICT 4, 5 (2010).
84 See Hendree E. Jones et al., Neonatal Abstinence Syndrome after Methadone or Bupre-
norphine Exposure, 363 N. ENG. J. MED. 2320, 2327 (2010) (finding no significant differences
in overall rates of NAS among infants exposed to buprenorphine and those exposed to metha-
done, but concluding that fetal exposure to the former results in shorter, less severe symptoms
than in utero exposure to the latter); Minozzi et al., Maintenance Agonist Treatments for Opi-
ate-dependent Pregnant Women, 12 COCHRANE DATABASE SYSTEMATIC REVS. 1, 2 (2013).
85 See Kocherlakota, supra note 48, at e549 (referring to the worsening of the spectrum of R
NAS, not only because of increased opioid use, but also because of the simultaneous use of
multiple opioids available with a prescription or on the street).
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A. Methadone – Lesser of Two Evils
In response to the post-World War II heroin epidemic in New York
City, methadone emerged in 1964 as a replacement treatment for opioid de-
pendence.86 Methadone is a long acting agonist that effectively occupies the
brain receptor sites also affected by heroin and other opioids.87 As the result
of occupying these opiate receptors, methadone blocks the euphoric and
sedating effects of opioids while relieving cravings and other symptoms as-
sociated with withdrawal.88 Methadone is considered a corrective treatment
rather than a cure for opioid misuse, and it has proven most successful when
administered for indefinite, or in some cases, life-long periods.89 The metha-
done maintenance treatment (MMT) model, which began as a research pro-
ject on six seasoned heroin misusers, has proved to be the most successful
treatment for opioid use disorder.90
Opioid misuse during a woman’s pregnancy subjects her and her fetus
to constant fluctuations of drug levels—a roller coaster of highs and lows
that can prove fatal to both the woman and her fetus.91 Aside from the sub-
stantial risk of overdose inherent in heroin and prescription pill dependence,
withdrawal symptoms can result in stillbirth, premature delivery, low birth
weight, and sudden infant death syndrome.92 Methadone, due to its long-
acting nature and capability to reduce cravings and stave off withdrawal
symptoms, promotes a healthier environment for the pregnant woman and
her fetus.93 Moreover, methadone maintenance reduces the incidence of
some medical and obstetrical complications germane to pregnant women
who misuse street drugs.94 Malnutrition, susceptibility to infectious diseases
such as HIV and hepatitis, premature rupture of membranes, pre-term labor,
and toxemia are examples of complications that are often thwarted by MMT
during pregnancy.95
Not surprisingly, a general comparison of heroin use and MMT during
pregnancy depicts the latter as the more desirable path for a pregnant woman
86 See Herman Joseph et al., Methadone Maintenance Treatment (MMT): A Review of
Historical and Clinical Issues, 67 MT. SINAI J. MED. 347, 347 (2000).
87 See id.
88 See id.
89 See id. at 361.
90 See id. at 348. A 1964 experiment conducted on six male heroin misusers at Rockefeller
University administered methadone to withdraw the test subjects from heroin. Id. Rather than
discontinuing the methadone once withdrawal symptoms subsided, the research team contin-
ued to administer methadone and study its effects. Id. As the patients adapted to methadone,
their cravings and obsession with drugs began to subside. Id. All six of these volunteers found
employment shortly after undergoing MMT. Id.
91 See id. at 355.
92 Id.
93 Id.
94 Id.
95 Id.
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and her fetus.96 In fact, MMT is currently the standard of care for treating
women who misuse opioids while pregnant.97 Notwithstanding its medical
and social acceptance, MMT certainly has its drawbacks, particularly when
administered to pregnant misusers.98 First, the severity and duration of with-
drawal symptoms exhibited by newborns exposed to methadone in utero are
substantial.99 Typically, infants born to methadone-maintained mothers cry
incessantly, respond poorly to visual stimuli, have less motor maturity, and
tend to be tremulous, irritable, and easily overexcited.100 Due to methadone’s
relatively long half-life, NAS symptoms are delayed; yet fetal exposure to
methadone yields longer, more severe withdrawal symptoms than NAS asso-
ciated with shorter-acting opioids, such as heroin.101 Second, the significant
increase in the number of pregnant opioid misusers treated with methadone
has contributed to a drastic rise in cases of NAS, both nationwide and in
Massachusetts.102 Indeed, the simultaneous increase in pregnant misusers
treated with methadone and infants born into methadone-induced abstinence
syndrome share a causal connection. The formation of this unfortunate and
extraordinarily costly nexus is one of the many dismal realities attributable
to the larger opioid epidemic.
B. Buprenorphine – A Step in the Right Direction
Initially introduced in France in 1996, buprenorphine was approved by
the United States Food and Drug Administration (FDA) as a treatment for
opioid dependence in October 2002.103 Buprenorphine is a partial agonist
that occupies the same receptors as methadone, and, unlike full agonist
medications, results in minimal withdrawal effects upon discontinuation.104
Suboxone is a unique formulation of buprenorphine that contains naloxone,
an opioid antagonist that limits diversion of the combined drug for recrea-
96 See id. at 356 (summarizing that the use of methadone fosters both a healthy infant and
a healthy mother).
97 Jones, supra note 84, at 2329.
98 See Hendree E. Jones et al., Buprenorphine Treatment of Opioid-dependent Pregnant
Women: A Comprehensive Review, 107 ADDICT. 5, 5 (2012).
99 See Rolley E. Johnson et al., Use of Buprenorphine in Pregnancy: Patient Management
and Effects on the Neonate, 70 DRUG & ALCOHOL DEPENDENCE S87, S88 (2003).
100 Id.
101 Id.; see also Carl Kuschel, Managing Drug Withdrawal in the Newborn Infant, 12
SEMINARS FETAL & NEONATAL MED. 127, 128 (2007).
102 See, e.g., Jennifer McKim & Michael Bottari, Cases of Newborns with Addictions
Soaring, BOS. GLOBE (Mar. 30, 2014), https://www.bostonglobe.com/metro/2014/03/29/explo
sion-drug-exposed-infants-reveals-weakness-massachusetts-child-protection/0ZhSZUhIBbn0j
VElOBgIsJ/story.html [https://perma.cc/X7RH-UQUX]. The majority of the 106 infants born
with NAS at Boston Medical Center in 2013 suffered withdrawal symptoms from in utero
exposure to methadone or buprenorphine. Id.
103 Johnson, supra note 99, at S98; see also THE N-SSATS REPORT: TRENDS IN THE USE OF
METHADONE AND BUPRENORPHINE AT SUBSTANCE ABUSE TREATMENT FACILITIES: 2003 TO
2011, supra note 81, at 1.
104 See Jones, Neonatal Abstinence Syndrome after Methadone or Buprenorphine Expo-
sure, supra note 84 at 2321.
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tional use by causing severe withdrawal symptoms in users who inject it to
get “high.”105 Both medications are available through clinics and office-
based practices by specifically certified physicians and have no adverse ef-
fects when taken orally, as prescribed.106 Due to insufficient clinical data,
suboxone is not a recommended medication for pregnant opioid misusers;
buprenorphine alone is considered the safest method of pharmacological
treatment.107
Whereas MMT during pregnancy often subjects the newborn to serious
and lengthy withdrawal symptoms, NAS associated with buprenorphine
treatment is shorter and clinically less severe than that observed with metha-
done.108 As a consequence of the comparatively mild NAS associated with
buprenorphine treatment of pregnant misusers, the mean length of NAS
treatment for infants born to such women is significantly shorter than the
average treatment for prenatally methadone exposed neonates.109
IV. A FORMULA FOR DISASTER – OXYCONTIN
AND LIBERAL PRESCRIPTIONS
“We have lost an entire generation. Half the pharmacies in Pike
County have bulletproof glass. We had FedEx trucks being
knocked off. It was the Wild West.”110
As developments in the arena of pharmacological treatment for sub-
stance use disorder continued to progress, the 1990s marked a relatively
peaceful period in America’s war on drugs.111 Drug-related violence dropped
105 See PRINCIPLES OF DRUG ABUSE TREATMENT FOR CRIMINAL JUSTICE POPULATIONS,
supra note 79, at 24.
106 See id.
107 See Ingunn O. Lund et al., A Comparison of Buprenorphine + Naloxone to Bupre-
norphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal
and Neonatal Outcomes, SUBSTANCE ABUSE RES. & TREATMENT 61, 72 (2013).
108 See Jones, Buprenorphine Treatment of Opioid-dependent Pregnant Women: A Com-
prehensive Review, supra note 98, at 5; see also Johnson, supra note 99, at S97 (acknowledg-
ing a mild to severe NAS in infants born to buprenorphine maintained mothers but noting that
such cases are less frequent, less severe, and of shorter duration).
109 Jones, Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure,
supra note 98, at 22. The mean duration of hospital stay for NAS treatment for 27 bupre-
norphine-exposed neonates in the MOTHER study was 9.7 days whereas the mean length of
hospital stay for NAS treatment of 41 prenatally methadone-exposed infants was 17.8 days. Id.
at 18.
110 David Armstrong, Purdue Says Kentucky Suit Over OxyContin Could Be Painful,
BLOOMBERG (Oct. 20, 2014), https://www.bloomberg.com/news/articles/2014-10-20/purdue-
says-kentucky-suit-over-oxycontin-could-be-painful [https://perma.cc/Z4VG-S8AQ]. These
are the words of Kentucky Attorney General Jack Conway in a statement to press declining
Purdue Pharma’s $500,000 settlement offer in connection with a civil suit filed by Kentucky
against Purdue.
111 See Roland G. Fryer et al., Measuring Crack Cocaine and its Impact, 51 ECON. IN-
QUIRY 1651 (2013) (finding that crack rose sharply beginning in 1985, peaked in 1989, and
slowly declined thereafter); see also Johnson, supra note 99, at S88.
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significantly, particularly in African-American communities.112 Due to so-
called “opiophobia”113 among physicians, substance use disorder rates were,
for the most part, temperate.114 This glimmer of hope was short lived as a
social enigma—one of the darkest and most complex that America has ever
faced—cast a portentous shadow over the nation.
In 1996, Purdue Pharma introduced OxyContin, the brand name for a
sustained release formula of oxycodone,115 designed to manage pain.116
Through aggressive advertising and marketing efforts, the company con-
ducted more than forty national conferences from 1996 through 2001,
through which it endorsed liberal prescription of opioids and promoted its
newly prepared formula, OxyContin.117 In 2001, Purdue’s sales representa-
tives, encouraged to sell the company’s newly designed painkiller in high
volumes, received an average bonus of $71,500 in addition to their $55,000
salary.118 Also in 2001, Purdue spent $200 million recruiting and training
physicians, pharmacists, and nurses to board the “OC” train and tout its
efficacy and safety.119 Utilizing state-of-the-art databases containing records
of prescribing practices of individual physicians, the pharmaceutical com-
pany identified and targeted its marketing efforts to those who prescribed
opioids frequently.120 A particular promotional strategy—uncomfortably, yet
strikingly similar to sales tactics of some street dealers—used a starter cou-
pon program for OxyContin, providing patients with a free, limited-time pre-
scription of the new product.121 By 2001, when the program ended,
approximately 34,000 coupons had been redeemed nationally.122
112 See Fryer, supra note 111, at 1655 (observing, by the year 2000, a correlation between
the decline in the impact of crack prevalence and the recovery of homicide rates in Black
communities).
113 The term refers to a doctor’s unwillingness or fear of prescribing opioids to patients.
Opiophobia, SEGEN’S MEDICAL DICTIONARY, retrieved from http://medical-www.merriam-
webster.com/dictionary.thefreedictionary.com/opiophobia [https://perma.cc/ERG4-3MN7]
(last visited Jan. 23, 2017).
114 Prior to the introduction of OxyContin, many physicians were reluctant to prescribe
opioids on a long-term basis because of their concerns about potential substance use disorder.
Andrew Kolodny et al., The Prescription Opioid and Heroin Crisis: A Public Health Approach
to an Epidemic of Addiction, 36 ANN. REV. PUB. HEALTH 559, 562 (2015).
115 Oxycodone is an opioid that produces heroin-like effects and is commonly used to treat
pain. Leanna Skarnulis, OxyContin: Pain Relief vs. Abuse, WEBMD (June 19, 2007), http://
www.webmd.com/pain-management/features/oxycontin-pain-relief-vs-abuse?page=5 [https://
perma.cc/VZS2-QWHG].
116 Id.; Art Van Zee, The Promotion and Marketing of OxyContin: Commercial Triumph,
Public Health Tragedy, 99 AM. J. PUB. HEALTH 221, 221 (2009).
117 See Van Zee, supra note 116, at 221.
118 Id. at 222.
119 Id. at 221. After its introduction, OxyContin quickly earned itself street names such as
Oxy, Oxycotton, hillbilly heroin, and blue. “OC” was one of the more common nicknames for
the drug.
120 Id. at 222.
121 Id.
122 Id.
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Purdue’s marketing campaign to use opioids to treat pain not associated
with a malignancy123 was a critical aspect of its success.124 As a result of
Purdue’s relentless promotion, OxyContin prescriptions for non-cancerous
pain increased ten-fold between 1997 and 2002, with non-cancer pain man-
agement accounting for eighty-six percent of opioid prescriptions nation-
wide.125 By 2004, OxyContin had become the most heavily misused opioid
in the United States.126 Purdue’s aggressive marketing strategies and the per-
suasive promotional efforts by its agents during a time of liberal prescribing
practices generated tremendous profit for the pharmaceutical company.127
Since its introduction twenty years ago, OxyContin sales have earned the
Sackler family, Purdue Pharma’s sole owners, $35 billion and the sixteenth
spot in the 2015 Forbes list of America’s richest families.128
What Purdue’s seemingly flawless campaign to promote OxyContin
failed to disclose, however, has likely caused irreparable harm to the pub-
lic.129 The thriving pharmaceutical company misrepresented the risks of ia-
trogenic130 addiction accompanying long-term use of the medication for non-
malignant pain.131 Sales representatives were instructed to carry the message
that risks of developing substance use disorder from OxyContin were less
than one percent.132 Although this percentage holds some validity when Ox-
yContin is used to treat acute pain, it grossly underrepresents the risks of
misuse that accompany long-term OxyContin use to manage chronic, non-
cancer-related pain.133 Purdue’s commercial success was further tarnished by
123 Cancer patients often experience pain which manifests in various ways. See Cancer
Pain Management, UNIV. OF TEX. MD ANDERSON CANCER CTR., https://www.mdanderson
.org/patients-family/diagnosis-treatment/emotional-physical-effects/cancer-pain-management
.html [https://perma.cc/TL4B-CYMS].
124 See Van Zee, supra note 116, at 225 (noting Purdue’s commercial success was fueled
by its unprecedented promotion and marketing campaign).
125 Id. at 223. Between 1997 and 2002, sales grew from 48 million in 1996 to almost 1.1
billion in 2000. Id.
126 Id. at 225.
127 See Alex Morrell, The OxyContin Clan: The $14 Billion Newcomer to Forbes 2015 List
of Richest U.S. Families, FORBES (July 1, 2015), http://www.forbes.com/sites/alexmorrell/
2015/07/01/the-Oxycontin-clan-the-14-billion-newcomer-to-forbes-2015-list-of-richest-u-s-
families/#50f12264c0e2 [https://perma.cc/EM4V-Q6W5].
128 Id.
129 See Van Zee, supra note 116, at 223 (referring to Purdue’s misrepresentation of the
risks of misuse associated with OxyContin).
130 Iatrogenic addiction is a substance use disorder “induced inadvertently by a physician
or surgeon or by medical treatment or diagnostic procedures.” Iatrogenic, MERRIAM-WEB-
STERMEDLINE PLUS ONLINE DICTIONARY, https://www.nlm.nih.gov/medlineplus/mplusdiction-
ary.html [https://perma.cc/5WS7-A3PY]. (last visited Feb. 1, 2015).
131 Id.
132 Id.
133 Studies have shown abuse rates among patients with opioid prescriptions for chronic
non cancer-related pain are quite substantial. See, e.g., Charles Chabal et al., Prescription
Opiate Abuse in Chronic Pain Patients: Clinical Criteria, Incidence, and Predictors, 13
CLINICAL J. PAIN 150, 150 (1997) (conducting a study where 34% of patients using opioids to
treat chronic pain met at least one of the criteria for abuse); Nathaniel P. Katz et al., Behav-
ioral Monitoring and Urine Toxicology Testing in Patients Receiving Long-Term Opioid Ther-
apy, 97 ANESTHESIA & ANALGESIA 1097, 1097 (2003) (“For 122 patients maintained on
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the inadequacy of OxyContin’s sustained-release mechanism.134 Almost im-
mediately, users learned to circumvent the pill’s time-release feature by re-
moving the outer film and crushing the tablet into a fine powder which could
be inhaled or injected, immediately giving the user an intense and euphoric
heroin-type high.135 These newly-found routes to administer the powerful
opioid and its general medical and social acceptance—a result of Purdue’s
aggressive marketing and misrepresentation of iatrogenic addiction associ-
ated with OxyContin—paved the way for a period of substance misuse that
would escalate to a full-blown epidemic.136
V. FEDERAL AND STATE REFORMATIVE ACTION
The solution to eradicating opioids is not a one-size-fits-all ap-
proach, and will require all of us to rethink the way we treat ad-
diction. Today’s announcements are a first step and we will
aggressively pursue reforms to save lives.137
Because the number of newborns treated for opioid withdrawal has
risen on a similar trajectory to that of the opioid misuse rate, it is foreseeable
that the number will decrease accordingly provided federal and state govern-
ments successfully overcome the larger crisis.138 With the opioid epidemic’s
devastating effects immediately apparent, many of America’s federal and
state government leaders are acting affirmatively to limit further suffering.139
chronic opioid therapy, 43% had a ‘problem’ (either positive urine toxicology or one or more
of the aberrant drug-taking behaviors).”); Edward Michna et al., Urine Toxicology Screening
Among Chronic Pain Patients on Opioid Therapy: Frequency and Predictability of Abnormal
Findings, 23 CLINICAL J. PAIN 173, 173 (2007) (An analysis of data from 470 urine screens
was performed. Samples were categorized as “normal” (expected findings based on their pre-
scribed drugs) or abnormal. Abnormal findings consisted of (1) absence of a prescribed opioid,
(2) presence of an additional non-prescribed controlled substance, (3) detection of an illicit
substance, and (4) an adulterated urine sample. Forty-five percent of the samples were
abnormal.).
134 See Van Zee, supra note 116, at 223.
135 See id.
136 See id. at 224 (correlating the high rates of opioid abuse and diversion with the high
availability of OxyContin); see also Kolodny et al., supra note 114 (noting a dramatic increase
in opioid-related overdose deaths, substance use disorder treatment admissions, and other ad-
verse health outcomes since 2002).
137 Governor Baker made this statement to the press following the release of his 65-step
plan to curb the opioid epidemic.
138 Massachusetts officials and doctors attribute the 1,700 infants born opioid-dependent
in 2014 to the statewide opioid crisis. See Levenson, supra note 25. Dr. Elisha Wachman, a
neonatologist at Boston Medical Center, calls prescription pills the driving force behind the
alarming number of infants born into withdrawal from substance exposure in utero. Id.
139 See DATABRIEF: FATAL OPIOID-RELATED OVERDOSES AMONG MASSACHUSETTS RE-
SIDENTS, supra note 9; see, e.g., Press Release, The White House: President Barack Obama,
Office of the Press Secretary, FACT SHEET: Obama Administration Announces Public and
Private Sector Efforts to Address Prescription Drug Abuse and Heroin Use (Oct. 21, 2015),
https://obamawhitehouse.archives.gov/the-press-office/2015/10/21/fact-sheet-obama-adminis-
tration-announces-public-and-private-sector [https://perma.cc/YJT6-FZCM] (On October 21,
2015, President Obama issued a memorandum to federal departments and agencies directing
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A. Federal Reformative Measures
A 2003 reauthorization of the Child Abuse and Prevention Treatment
Act (CAPTA) directed states to implement policies and procedures for re-
porting substance-exposed newborns to child protection services (CPS)
agencies in order to receive federal funding.140 The bill amending CAPTA,
commonly referred to as the Keeping Children and Families Safe Act, re-
quires health care providers to notify CPS of infants born and identified as
affected by maternal substance misuse or withdrawal symptoms resulting
from prenatal substance exposure.141 The law also mandates that state CPS
agencies develop safe recovery plans for such substance-exposed
newborns.142 Currently, all fifty states and the District of Columbia have stat-
utes conveying CAPTA’s notification and recovery development plan
requirements.143
Massachusetts, which abides by CAPTA’s mandates in its reporting
statute,144 received a $3.5 million federal grant in August 2015 to assist hos-
pitals and health systems in the management and care of the overwhelming
number of infants diagnosed with NAS.145 The Health Policy Commission
(HPC), an independent state agency that develops policy to improve the
quality of health care throughout Massachusetts,146 matched the federal
them to implement prescriber training programs and expand access to treatment.); FINDINGS OF
THE OPIOID TASK FORCE AND DEPARTMENT OF PUBLIC HEALTH RECOMMENDATIONS ON PRIORI-
TIES FOR INVESTMENTS IN PREVENTION, INTERVENTION, TREATMENT AND RECOVERY, supra
note 10, at 1 (In 2014, former Massachusetts Governor Deval Patrick declared the opioid crisis
an epidemic, instructing the Department of Health to craft long-term solutions to combat
opioid misuse in the Commonwealth.); VT. ASS’N FOR MENTAL HEALTH AND ADDICTION RE-
COVERY, THE SCOPE OF THE OPIATE CRISIS IN VERMONT (Pear Vermont Publications, 2015)
(Since Vermont Governor Peter Shumlin dedicated his entire 2014 state of the state message to
what he called a “full-blown heroin crisis,” Vermont has implemented several programs and
resources to address the opioid epidemic.).
140 See Child Abuse and Prevention Treatment Act, 42 U.S.C. § 5106(a)(1)(B) (2012)
(“The Secretary may award grants to public or private organizations . . . to improve the recruit-
ment, selection, and training of volunteers serving in public and private children, youth, and
family service organizations in order to prevent child abuse and neglect.”).
141 See Keeping Children and Families Safe Act of 2003, Pub. L. No. 108-36, 117 Stat.
800 (codified as amended at 42 U.S.C. § 5106, 5106(b)(2)(B)(i) (2012)).
142 See 42 U.S.C. § 5106(b)(2)(B)(ii) (2012).
143 NAT’L CONFERENCE OF STATE LEGISLATURES, MANDATORY REPORTING OF CHILD
ABUSE AND NEGLECT STATUTES 1 (2011), http://www.ncsl.org/research/human-services/child-
abuse-and-neglect-reporting-statutes.aspx [https://perma.cc/WG68-2L8J].
144 See MASS. GEN. LAWS ch. 119, § 51A(a)(iii) (2012) (“A mandated reporter who, in his
professional capacity, has reasonable cause to believe that a child is suffering physical or
emotional injury resulting from . . . physical dependence upon an addictive drug at birth, shall
immediately communicate with the department orally and, within 48 hours, shall file a written
report with the department detailing the suspected abuse or neglect.”).
145 Katie Lannan, New Program Targets Growing Problem of Newborns Exposed to
Drugs,  HERALD NEWS (Dec. 23, 2015, 9:07 AM), http://www.heraldnews.com/article/201512
23/NEWS/151228297 [https://perma.cc/DU9N-Z2NK].
146 See The Official Website of the Executive Office for Administration and Finance,
Health Policy Commission, http://www.mass.gov/anf/budget-taxes-and-procurement/over-
sight-agencies/health-policy-commission/ [https://perma.cc/TVS3-6N7X].
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award with $3.5 million from its own funds, $500,000 of which is desig-
nated to launching the delivery-to-discharge initiative.147 The overarching
goal of the delivery-to-discharge project seeks to reduce the total cost of
NAS-related care by adopting evidence-based practices and successful pro-
grams used in other regions.148 The pilot program will implement a detailed
model of post-natal support for substance-exposed newborns and their fami-
lies in up to three Massachusetts medical facilities.149 HPC executive director
David Seltz envisions the delivery-to-discharge program reducing length of
hospital stays and the need to intensively treat substance-exposed newborns,
resulting in substantial savings in NAS-related expenditures.150
Less than six months after Massachusetts announced its plan to move
forward with the delivery-to-discharge project, Congress passed legislation
in an effort to stifle nationwide increases in NAS.151 Like the Common-
wealth’s delivery-to-discharge program, but on a larger scale, the Protecting
Our Infants Act of 2015 was designed to identify evidence-based approaches
to care for mothers who misuse opioids and newborns withdrawing from in
utero opioid exposure.152 The act requires the U.S. Secretary of Health and
Human Services to identify gaps in research concerning the most appropriate
types of treatment for pregnant opioid misusers, the most effective ways to
treat NAS, and the long-term effects of in utero opioid exposure on chil-
dren.153 The act also charges the Secretary of Health and Human Services
with identifying gaps or overlap in federal substance use disorder treatment
programs for pregnant and postpartum women, treatment options for infants
with NAS, and federal efforts to prevent NAS.154 A noteworthy provision of
the Protecting Our Infants Act of 2015 instructs the Secretary of Health and
Human Services to catalogue research and findings into a report, evaluating
current efforts to manage NAS and recommending ideas to improve NAS
prevention and treatment.155 Upon completion, the report shall be submitted
to the Committee on Health, Education, Labor, and Pensions of the Senate
and the Committee on Energy and Commerce of the House of Representa-
tives to ensure future legislation relative to NAS management is narrowly
tailored to address the most current data.156
147 Id.; COMMONWEALTH OF MASS. HEALTH POL’Y COMM’N, QUALITY IMPROVEMENT AND
PATIENT PROTECTION COMMITTEE 31 (2015).
148 COMMONWEALTH OF MASS. HEALTH POL’Y COMM’N, supra note 147, at 31.
149 See id.
150 See Lannan, supra note 145.
151 The Protecting Our Infants Act of 2015 was enacted on November 18, 2015. Protecting
Our Infants Act of 2015, Pub. L. No. 114-91, 129 Stat. 723, 723–25 (2015).
152 See generally Protecting Our Infants Act of 2015 (The Secretary of Health and Human
Services shall review current programs that focus on managing NAS, address gaps in such
programs, and develop recommendations to expand and improve current treatment and preven-
tion measures.).
153 See Protecting Our Infants Act of 2015, 129 Stat. at 723.
154 Id.
155 129 Stat. at 724.
156 129 Stat. at 723.
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In addition to the 2003 amendment to CAPTA and the Protecting Our
Infants Act of 2015, there are other recent and ongoing federal initiatives
geared toward ensuring pregnant women who struggle with substance use
disorder have access to prenatal care as well as effective and safe treatments.
The Centers for Disease Control and Prevention (CDC), continues to assist
states in improving the availability and quality of NAS-related data, encour-
aging collaborative public health measures to decrease its prevalence.157 The
CDC’s “Treating for Two”158 initiative, a movement to improve the availabil-
ity and quality of data with intentions of producing better informed decisions
concerning prescription medication during pregnancy, has included opioid
use during pregnancy in its research, emphasizing the importance of reduc-
ing unnecessary risks if and when possible.159 Another example of recent
federal action addressing the NAS issue was carved into the Obama Admin-
istration’s 2015 National Drug Control Strategy (NDCS).160 In its fifth year
of existence, the 2015 NDCS set goals to reduce NAS through collaborative
efforts within states and smaller communities, develop treatment guidelines
for opioid-dependent pregnant women, and publish guidelines encouraging
providers to safely prescribe pain medications to pregnant women with
chronic pain.161 These initiatives show that the opioid epidemic has attracted
nationwide attention.
B. Aggressive STEPs Forward in Massachusetts
Under Governor Baker’s leadership, Massachusetts has taken strong ini-
tiatives to address the opioid epidemic by making the Commonwealth’s work
to curb opioid misuse a top priority.162 In addition to the sixty-five step plan
to confront the epidemic head on, Governor Baker charged the Massachu-
setts Drug Formulary Commission with the task of ensuring that opioids
157 Michael Botticelli, Protecting Our Infants, THE WHITE HOUSE: PRESIDENT BARACK
OBAMA (Nov. 25, 2015, 4:26 PM), https://obamawhitehouse.archives.gov/blog/2015/11/25/
protecting-our-infants [https://perma.cc/MY37-VMSH].
158 The CDC’s Treating for Two Initiative aims to improve the health of women and babies
by working to identify the safest treatment options for the management of common conditions
before and during pregnancy. The initiative aligns with three key drivers of safer medication
use in pregnancy: better research, reliable guidance, and informed decisions. Treating for Two,
CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/pregnancy/meds/ treat-
ingfortwo/aboutus.html [https://perma.cc/T8AX-LRHK].
159 The NDCS is an official report produced annually by the Office of National Drug
Control Policy. Piloted in 2010, the NDCS outlines the Obama Administration’s efforts to
reduce illicit drug use, manufacturing and trafficking, drug-related crime and violence, and
drug-related health consequences. OFFICE OF NAT’L DRUG CONTROL POL’Y, NAT’L DRUG CON-
TROL STRATEGY (2015).
160 See generally id.
161 Id. at 101.
162 See Governor Announces New Panel on Opioids, supra note 18; see also MA Governor
Baker Announces Initial Steps To Combat Opioid Addiction Crisis, supra note 19.
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comport with the latest misuse deterrent mechanisms.163 The Commission,
originally established to create a drug formulary, or list of interchangeable
drug products, for use by health care providers and pharmacists in an effort
to raise consumer awareness to cost-effective alternatives,164 now assesses
and evaluates the most powerful opioids for four components—accessibility,
cost, effectiveness, and misuse-deterrent properties.165 When two drugs are
chemically equivalent, but only one has misuse-deterrent properties, the
Commission may deem this drug “interchangeable” with the non-deterrent
formula.166 The new formulary will assume a role in containing the opioid
epidemic by providing clinicians with the safest options to manage pain in
patients at risk for substance use disorder.167 Massachusetts Department of
Health Commissioner, Monica Bharel, a key player in the Commonwealth’s
efforts to curtail opioid use disorder rates, views implementation of the mis-
use deterrent plan as a critical step forward in the cross-disciplinary initiative
to prevent opioid use disorder.168
In October of 2015, Governor Baker drafted a bill entitled “An Act
Relative to Substance Use Treatment, Education, and Prevention” (hereinaf-
ter referred to as the “STEP Act”) which urged the legislature to promptly
enact specific measures to improve statewide opioid misuse prevention, in-
tervention, treatment, and recovery services.169 The STEP Act identified
availability, over-prescription, and misuse of prescription opioids as the
leading causes of the opioid epidemic.170 Moreover, the Act proposed some
sweeping measures to limit prescribing practices, to enhance detection and
prevention, to implement treatment, and to ensure that insurance companies
comply with federal laws relative to the availability of coverage for sub-
stance use disorder treatment.171
In March 2016, and after weeks of intensive review, the STEP Act
passed with unanimous votes in both the Senate and the House.172 Multiple
163 Press Release, The Official Website of the EOHHS, Governor Names Drug Formulary
Commission on Opioids (Aug. 3, 2015) http://www.mass.gov/eohhs/gov/newsroom/press-re-
leases/eohhs/governor-names-drug-formulary-commission-on-opioids.html [https://perma.cc/
3KYJ-2PCP].
164 See 105 Mass. Code Regs. § 720.001 (2016).
165 Id.
166 Id.
167 The Official Website of the EOHHS, Governor Names Drug Formulary Commission
on Opioids, supra note 163.
168 See id. “While the majority of opioids are prescribed and used responsibly, every step
we can take to prevent the opportunity for misuse is a critical step forward.” Id.
169 H.R. 4209, 189th General Court, Reg. Sess. (Ma. 2015).
170 See generally id.
171 See id.; see also Nora D. Volkow et al., Medication-Assisted Therapies—Tackling the
Opioid Overdose Epidemic, 370 NEW ENG. J. MED. 2063, 2065 (2014) (explaining that the
Affordable Care Act (ACA) extends the reach of the Mental Health Parity and Addiction Eq-
uity Act, which requires insurance plans offering coverage for mental health or substance-use
disorders provide the same level of benefits that they do for general medical treatment).
172 Press Release, The Official Website of the Governor of MA, Governor Baker Signs
Landmark Opioid Legislation into Law (March 14, 2016), http://www.mass.gov/governor/
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provisions of the bill contained proposals from Governor Baker’s draft, in-
cluding the controversial173 law limiting first-time opioid prescriptions to a
seven-day supply, subject to narrow exceptions promulgated at the discre-
tion of the Commissioner of Public Health.174 Another notable provision of
the STEP Act extracted from Governor Baker’s draft requires that informa-
tion on opioid misuse be incorporated in annual head injury safety programs
for high school athletes.175 Requirements that physicians, dentists, and other
persons who prescribe controlled substances complete at least five hours of
training every two years on the risks of misuse associated with prescription
opioids were also adopted as originally proposed by the Governor in the
bill’s initial draft.176 A final piece of the original draft to remain intact
throughout the deliberation process imposes a legal requirement that all
prescribers enroll in and utilize the Prescription Monitoring Program (PMP)
before issuing opioid prescriptions.177
Another component of the legislation focuses on enhancing the efficacy
of opioid abuse detection and prevention protocol.178 Adults best positioned
to detect and prevent opioid misuse among young people will be required to
receive regular training on the dangers associated with prescription painkil-
lers.179 Prompt implementation of this training in venues such as high
schools and universities will increase awareness of the signs and symptoms
of misuse, ultimately providing a better first-line defense against opioid use
disorder.180
press-office/press-releases/fy2016/governor-signs-landmark-opioid-legislation-into-law.html
[https://perma.cc/7HFG-WA3J].
173 Dr. Dennis Dimitri, president of the Massachusetts Medical Society, opposed a limit on
first time opioid prescriptions stating, “[I]t doesn’t necessarily allow for the clinical judgment
of physicians – to adjust their prescriptions for different patients with different situations.”
Joshua Miller, Facing Epidemic, Baker Seeks to Limit Opioid Prescriptions, BOS. GLOBE (Oct.
15, 2015), https://www.bostonglobe.com/metro/2015/10/15/baker-unveil-opioid-bill-looking-
address-crisis/JY30aFl1N5s QlHz4kKSRiL/story.html [https://perma.cc/6HUD-T8U7]. Dr.
David P. Lustbader, oral surgeon and vice president of the Massachusetts Dental Society,
referred to the limit as a simplistic approach to a complex problem. Id. Dr. Patrice A. Harris,
chairwoman-elect of the American Medical Association (AMA), expressed the AMA’s “con-
cerns over sections of the bill, including universal mandates that may be well-intentioned, but
may have unintentional consequences to the patient-physician relationship.” Id.
174 Governor Baker Signs Landmark Opioid Legislation into Law, supra note 172.
175 Id.
176 Id.
177 See id.; see also MA DEP’T PUB. HEALTH, THE MASSACHUSETTS PRESCRIPTION MONI-
TORING PROGRAM: A REPORT TO THE MASSACHUSETTS GENERAL COURT 4–5 (2015) (The
PMP, established in 1992, serves as a repository of data for all Schedule II – V prescription
drugs dispensed in the Commonwealth. The PMP enables health care providers to look into a
patient’s prescription drug history and make informed decisions in regard to opioid prescrip-
tion. Prior to 2012, PMP enrollment was voluntary for prescribers. However, Chapter 244 of
the Acts of 2012, and a series of minor statutory amendments thereafter, mandated enrollment
of all prescribers.).
178 H.R. 4209.
179 Id.
180 Id.
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During the draft phase, a piece of Governor Baker’s legislation did walk
a fine constitutional line by authorizing compulsory treatment for the sickest
of misusers.181 This provision of the STEP Act had permitted a physician to
hold a patient for an initial three-day (72-hour) period at a hospital or treat-
ment center if the physician determined that the patient suffered from a sub-
stance use disorder and that a failure to treat the patient would have
presented a serious risk of harm.182 The provision required a physician who
would have held a patient for emergency treatment to encourage the patient
to consent to treatment. The physician would also have been permitted to
seek a court order for an involuntary ninety-day inpatient treatment should
the patient have refused consent.183
This 72-hour hold and physician-elected involuntary treatment did not
survive the draft phase of the STEP Act and were not ultimately included in
its final passage.184 Without these original extremes, the version that was
passed survives as a reflection of the work cut out for Massachusetts in con-
fronting the opioid epidemic and also the Commonwealth’s strong resolve in
ameliorating this issue.
As political leaders continue collaborating proactively to reduce NAS
rates and opioid misuse at both federal and state levels, individual communi-
ties must also continue the offensive against the epidemic. The time is ripe
for developing reformative ideas and creating solutions to contain NAS
rates, and the ominous opioid epidemic from which they have snowballed.
Relentless multi-sector approaches and proposals—from all stakeholders—
are key ingredients to curbing the epidemic and “taking back the town.”
VI. FACILITATIVE RENOVATIONS – A PREVENTATIVE SYSTEM TO
SUPPRESS NEONATAL ABSTINENCE SYNDROME
Government bodies may promote maternal and infant health by imple-
menting systems that adhere to one of two general structures.185 The adver-
sarial model, frequently utilized in the 1980s in response to the “crack
baby”186 crisis resulting from a national cocaine epidemic, views the woman
181 See id.
182 Id.
183 Id.
184 See generally Act Relative to Substance Use, Treatment, Education, and Prevention,
2016 Mass. Acts, ch. 52.
185 See generally Dawn Johnsen, Shared Interests: Promoting Healthy Births without Sac-
rificing Women’s Liberty, 43 HASTINGS L. J. 569, 571 (1992) (referring to the two dramatically
different governmental approaches to promote the health of newborns).
186 See generally David F. Chavkin, “For Their Own Good”: Civil Commitment of Alcohol
and Drug-Dependent Women, 37 S.D. L. REV. 224 (1992). According to the National Institute
on Drug Abuse, 15% of women of child bearing age regularly abused substances in 1989. Id.
at 230. Experts attribute this notable increase to the wide spread availability of crack-cocaine
and its popularity among women. Id. at 230–31. Due to its effect on women of child bearing
age, the infant population was also impacted by the national spike in cocaine use among wo-
men. Id. at 231. In utero exposure to cocaine often causes lower birth weight, withdrawal and
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and fetus as distinct legal entities with adverse interests.187 This view oper-
ates on the assumption that the government’s role is to protect the unborn
from its expectant mother.188 Often times an adversarial approach to promote
fetal rights involves criminal prosecution for a woman’s conduct while preg-
nant.189 A recently expired Tennessee sunset law,190 enacted in 2014 to incen-
tivize pregnant misusers to seek treatment, is a prominent example. The
controversial Tennessee fetal assault law authorized prosecution of misusers
bearing chemically-dependent children as a result of narcotics misuse during
pregnancy.191 A provision in the statute considered it an affirmative defense
if the woman enrolls in a recovery program before giving birth, remains in
the program after giving birth, and successfully completes the program.192
The defense applied regardless of the newborn’s abstinence-related inju-
ries.193 Failing to achieve its intended purpose and having produced unin-
tended consequences194 that conflicted with state interests in maternal and
infant health, Tennessee’s fetal assault law was not renewed by its June 30,
2016 expiration date.195
The second general methodology by which the government may pro-
mote infant and maternal health and welfare presumes that the pregnant wo-
man and state share an interest in promoting healthy childbirth.196 This
notion—a facilitative approach—strives not to punish women affected by
substance use disorder during pregnancy, but aims to form a more harmoni-
ous relationship whereby the government assists pregnant misusers in mak-
ing choices most likely to further a common objective—the best interests of
irritability after birth, smaller head circumference, and long-term learning disabilities. Id. at
233.
187 Johnsen, supra note 185, at 571.
188 Id.
189 See id. at 577 (illustrating three instances where women were prosecuted under statutes
that were not intended to criminalize a woman’s conduct during pregnancy).
190 A sunset law is a statute under which a governmental agency or program automatically
terminates at the end of a fixed period unless it is formally renewed. Sunset law, BLACK’S LAW
DICTIONARY (9th ed. 2009).
191 See TENN. CODE ANN. § 39-13-107 (2014).
192 Alleged violators were charged under Tennessee’s assault statute. TENN. CODE ANN.
§ 39-13-101 (West 2014).
193 TENN. CODE ANN. § 39-13-107 (2014).
194 See Mallory Yu et al., In Tennessee, Giving Birth To A Drug-Dependent Baby Can Be A
Crime, ALL THINGS CONSIDERED, NPR (Nov. 18, 2015, 3:22 PM), http://www.npr.org/sec-
tions/health-shots/2015/11/18/455924258/in-tennessee-giving-birth-to-a-drug-addicted-baby-
can-be-a-crime [https://perma.cc/L825-7ZVM] (explaining that substance-dependent women,
like Brittany Crowe, were afraid of the law and neglected to seek proper medical care during
pregnancy).
195 TENN. CODE ANN. § 39-13-107 (2014), amended by An Act to Amend Tennessee Code
Annotated, Title 39, relative to Criminal Law, Pub. L. No. 820, § 1391 (July 1, 2016); see
Clint Cooper, Fetal Assault Law Rightly Will Sunset, TIMES FREE PRESS (Mar. 26, 2016), http://
www.timesfreepress.com/news/opinion/freepress/story/2016/mar/26/cooper-fetal-assault-law-
rightly-will-sunset/357198/ [https://perma.cc/K6H3-ZMYK].
196 See Johnsen, supra note 185, at 573.
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woman and child.197 Inherent within the facilitative model is an appreciation
for the concept that the vast majority of pregnant women who use illicit
substances do so because they are affected by a disease of the brain, not
because they desire to give birth to an unhealthy infant.198 Hence, a success-
ful facilitative policy is one that helps pregnant misusers overcome adversity
and equips them with the resources necessary to deliver a healthy child.199
Fortunately, Massachusetts policymakers recognize that the facilitative
approach is better suited to manage the current opioid epidemic than its ad-
versarial alternative. The multi-dimensional efforts demonstrated by Gover-
nor Patrick’s Opioid Task Force,200 Governor Baker’s sixty-five step
collaborative plan,201 the Health Policy Commission’s federally backed deliv-
ery-to-discharge program,202 the Massachusetts Opioid Drug Formulary
Commission’s creation,203 and other state-led initiatives, have sought to
achieve the end-state goal of containing the epidemic through similar
facilitative approaches, all of which are grounded in collaboration.204 A
bird’s-eye view of these cross-disciplinary group efforts to confront the epi-
demic reveals facilitative commonalities geared toward expanding access to
treatment, updating data through rigorous research, educating patients, fami-
lies, and prescribers, implementing safe prescribing practices, and reducing
the stigma of substance abuse disorders.205 As Commonwealth leaders have
197 See id. at 613 (concluding that government, women, and future children all have shared
interests in taking the steps necessary to promote healthy births).
198 See id. at 575 (noting that the majority of women with substance use disorder continue
to misuse during pregnancy because they suffer from strong physical and psychological depen-
dencies developed prior to conception, not because they desire to give to birth to an unhealthy
baby).
199 See id. at 574.
200 See supra notes 10–17 and accompanying text.
201 See RECOMMENDATIONS OF THE GOVERNOR’S OPIOID WORKING GROUP, supra note 20,
at 2 (recognizing an effective response to the opioid epidemic requires strong partnerships
between the medical community, law enforcement, the judiciary, insurers, providers, health
and human services agencies, elected officials, and the public).
202 See supra notes 147–150 and accompanying text. R
203 See supra notes 163–167 and accompanying text.
204 See, e.g., Press Release, The Official Website of the EOHHS, Baker-Polito Administra-
tion, MA Dental Schools, and the MA Dental Society Announce Dental Core Competencies to
Combat the Opioid Epidemic (Feb. 11, 2016) http://www.mass.gov/eohhs/gov/newsroom/
press-releases/eohhs/dental-core-competencies-to-combat-addiction-announced.html [https://
perma.cc/T664-YQHU] (“Dental medicine has an expanding role in promoting public health,
with an increased attention to inter-professional collaboration across a range of healthcare
disciplines. The need for this collaborative effort is most evident when the patient presents
with complex medical and psychiatric comorbidities.”).
205 See RECOMMENDATIONS OF THE GOVERNOR’S OPIOID WORKING GROUP, supra note 20,
at 7–9 (recommending strategies to develop new pathways to treatment, increase access to
medication-assisted treatment, abolish the stigma of substance abuse disorders, support sub-
stance use prevention education in schools, and require all practitioners to receive training
about addiction and safe prescribing practices); see also FINDINGS OF THE OPIOID TASK FORCE
AND DEPARTMENT OF PUBLIC HEALTH RECOMMENDATIONS ON PRIORITIES FOR INVESTMENTS IN
PREVENTION, INTERVENTION, TREATMENT AND RECOVERY, supra note 10, at 1 (summarizing
the findings of Governor Patrick’s Opioid Task Force and recommending action, including, but
not limited to: the expansion of treatment beds; the formation of a centralized system for
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acknowledged, a collaborative offensive is most effective when all members
of the community are on board, with those directly affected by the epidemic
playing a particularly vital role.206
A. Mandatory Reporting is Insufficient
The grave increase in statewide neonatal abstinence rates germane to
the opioid crisis has reached a level that warrants immediate action. At the
present time, Massachusetts is ill-equipped to effectively deal with the inor-
dinate number of opioid-dependent newborns. Although well-intended, the
Commonwealth’s mandatory reporting statute, standing alone, does not pack
the requisite punch to adequately deal with the opioid epidemic. The law—
the sole means of statutory redress for babies born with neonatal abstinence
syndrome—requires physicians, nurses, and other hospital personnel with
reasonable cause to believe a newborn is suffering from physical withdraw-
als to immediately notify the Massachusetts Department of Children and
Families (DCF).207 The physician, nurse, or other personnel who suspects the
infant is withdrawing from in utero substance exposure must file a written
report with the DCF detailing the observations leading to the suspected
abuse or neglect within forty-eight hours.208 By identifying maternal sub-
stance abuse within the first few days of an infant’s birth, the statute permits
early intervention to serve the child’s postnatal interests. In most cases,
newborns displaying withdrawal symptoms return to their families after a
detoxification period at the hospital because the DCF does not have the re-
sources to deal with the inundation of babies born with neonatal abstinence
syndrome.209 As such, the current explosion of opioid-dependent newborns
patients, families, and first responders to locate treatment services; additional opioid preven-
tion coalitions for support and education; and more stringent safeguards for those opioids,
which are most frequently abused and misused).
206 See, e.g., Julie Beck, Any Addict Who Asks for Help Will NOT Be Charged’, ATLANTIC
(May 11, 2015), http://www.theatlantic.com/health/archive/2015/05/gloucester-massachusetts-
police-department-helping-not-arresting-drug-addicts/392873/ [https://perma.cc/8AED-
Y3EP] (referring to a new policy in Gloucester, MA whereby a person who misuses sub-
stances and voluntarily walks into the police department, surrenders his or her drugs, and asks
for help, will not be charged. Rather, the person will be assigned an “angel” who will immedi-
ately begin to guide the person toward treatment and recovery).
207 See MASS. GEN. LAWS ch. 119, § 51A(a) (2012); see also MASS. GEN. LAWS ch. 119,
§ 21 (2013) (Defining A mandated reporter as “a person who: (i) a physician, medical intern,
hospital personnel engaged in the examination, care or treatment of persons, medical exam-
iner, psychologist, emergency medical technician, dentist, nurse, chiropractor, podiatrist, op-
tometrist, osteopath, allied mental health and human services professional licensed under
section 165 of chapter 112, drug and alcoholism counselor, psychiatrist or clinical social
worker.”).
208 See MASS. GEN. LAWS ch. 119, § 51A(a).
209 See McKim & Bottari, supra note 27 (Most substance-exposed newborns, like Mya
Barry, return to their families despite DCF’s awareness that the mother misuses substances. In
Mya’s case, DCF officials permitted Mya to go home with her father and grandfather provided
that her mother would have no unsupervised time with Mya. According to child welfare ex-
perts, there is an inherent weakness in these types of arrangements, as parents with substance
use disorders often manipulate or coerce such designated caretakers.).
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has exacerbated a pre-existing defect within the Commonwealth’s children’s
services agency, burdening an already overstretched DCF well beyond
capacity.
Aside from the mandatory reporting statute’s futile effects on ensuring
postnatal health and wellness of children, neonatal abstinence syndrome pre-
ventative measures are not included within the scope of the law. Rather,
predicated upon principles of intervention, the statute essentially identifies
infants harmed by in utero exposure to substances and intervenes post-
natally to protect newborns from further harm by mothers who continue to
misuse. Neither the mandatory reporting statute itself, nor the child protec-
tion services which it triggers, is capable of managing the sizeable upswing
of infants born opioid-dependent during the current epidemic.
B. Proposal for Reform – Facilitative Prevention through
Aggressive Identification
Massachusetts has demonstrated, through multi-dimensional collabora-
tive initiatives to hinder the epidemic’s destructive momentum, an intuitive
awareness that existing legal frameworks are not sufficiently robust to de-
fend against such an intense wave of substance use disorder. With the Baker
administration leading the charge, all Commonwealth residents who have
joined the fight to resolve the current crisis should be applauded for their
support. As policymakers continue to formulate solutions to the epidemic,
and legislators deliberate on recently proposed bills, Massachusetts should
consider adopting a uniform facilitative system designed to reduce the ag-
gregate of NAS diagnoses through preventative measures. A successful plan
adheres to facilitative principles, yet is implemented aggressively to be com-
mensurate with the severity of the issue. The system aims to lower the state-
wide NAS rate by preventing the disorder through a comprehensive plan
predicated upon early identification of substance use during pregnancy. To
achieve optimal success, the plan should not only be carried out promptly
and aggressively, but should be adopted uniformly throughout the
Commonwealth.
Identification is the imperative component of the proposed model. De-
tecting opioid misuse among pregnant patients at the earliest possible point
in gestation permits providers to make appropriate treatment referrals to fur-
ther maternal and child health interests. The identification process shall com-
mence at the patient’s first prenatal visit.210 The examining nurse or
physician, adhering to a statewide standard, educates the patient, orally and
in writing, on the current opioid epidemic and the toll it has taken on
newborns, hospitals, and the community as a whole. The provider shall fur-
ther explain that all Massachusetts hospitals are taking a new approach to
210 A gestation period is the timespan between conception and labor. In humans the period
is approximately 38 weeks. Gestation Period, MOSBY’S MED. DICTIONARY (9th ed. 2009).
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prevent the problem from further expansion. The provider shall also inform
the patient that communication and disclosures made during prenatal ap-
pointments, and information gathered through the Commonwealth’s new as-
sessment protocol, are strictly reserved for the purpose of protecting
maternal and fetal heath interests.211 The patient shall be further advised that
all information volunteered in regard to substance use of any kind is af-
forded a high degree of privacy, and will be strictly protected from access by
law enforcement or other outside entities. The information may, however, be
transmitted to a substance use disorder professional for further evaluation.
Specialized women’s treatment providers may also access the content
gleaned from the assessment should the substance use disorder professional
believe treatment is necessary to promote maternal and fetal health. In com-
pliance with the tenets of informed consent and general fairness principles,
patients shall be notified of the mandatory reporting statute that is triggered
after the child is born.
All patients are screened with a standardized tool,212 deemed efficacious
and reliable among substance misuse and behavioral health experts. All
screenings, regardless of the patient’s self-reports and clinical history, are
supplemented with a toxicology test to corroborate self-evaluations and en-
sure screening accuracy.213 Toxicology tests shall be standardized throughout
the state, conforming with the latest advances in science and technology.
Patients who fall under one of four categories are referred to a substance use
disorder professional with training and experience treating pregnant women
who misuse opioids. The four categories are: (1) screens that indicate any
opioid use during pregnancy; (2) current MAT or other treatment for opioid
dependence; (3) clinically documented or self-reported opioid abuse within
the last two years; and (4) toxicology tests showing presence of opioids.
211 Essential to a successful policy of this nature is the patient’s trust and confidence in her
examining nurse or physician. As such, the provider shall ensure the patient is aware of the
confidentiality of the doctor-patient relationship, emphasizing its applicability at the present
time, and in all future pre or post-natal visits.
212 The DAST-10, a ten-item questionnaire that can be administered in an interview or
self-report format, is an example of a universally accepted screening tool that should be con-
sidered for uniform implementation in this policy. See Instrument: Drug Abuse Screening Test
(DAST-10), NIDA CTN Common Data Elements, https://cde.drugabuse.gov/instrument/e9053
390-ee9c-9140-e040-bb89ad433d69/module/e9053390-eea5-9140-e040-bb89ad433d69 [https:
//perma.cc/YU6W-XVE4].
213 State imposed toxicology tests have gained considerable attention in Fourth Amend-
ment jurisprudence. In 2001, the United States Supreme Court declared urine tests adminis-
tered to pregnant patients based on certain government generated criteria were unreasonable
searches because the test results were turned over to the police for purposes of prosecution.
Ferguson v. City of Charlestown, 532 U.S. 67, 85–86 (2001). The Court, finding the specific
purpose of the policy was designed to incriminate patients without a warrant or probable cause,
ruled the toxicology testing policy unconstitutional. Id. at 86. The policy proposed in this
Article will successfully overcome challenges on Fourth Amendment grounds because the tox-
icology tests are administered solely for the medical purposes of promoting maternal and child
health and welfare. Furthermore, the proposed model expressly excludes law enforcement in-
terests, precluding the admissibility of prenatal toxicology tests in any subsequent court pro-
ceedings in which the patient is a party.
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The substance use disorder professional further evaluates patients mak-
ing factual and circumstantial decisions concerning treatment on a case-by-
case basis.214 Patients falling into one of the four categories above that are
subsequently determined by the substance use disorder professional not to
misuse are encouraged to follow up with the evaluator over the course of the
pregnancy to ensure continued accuracy of the original evaluation. Follow-
up appointments shall be scheduled as agreed upon by the evaluator and
patient. Patients requiring treatment are referred to a specialized women’s
treatment center. The treatment center integrates the latest and most effective
opioid use disorder treatment with medical services related to pregnancy and
birth. Providing pregnant opioid misusers with comprehensive treatment and
prenatal care optimally serves maternal, child, and governmental interests.
Such a facilitative approach, if implemented in public hospitals throughout
the Commonwealth, would decrease opioid use disorder during pregnancy,
thereby reducing statewide NAS rates.
Upon arriving at the specialized women’s treatment center, patients
shall undergo further screening and another toxicology test as part of a pro-
cess that classifies the severity of the disorder. This part of the identification
phase shall use a standardized operational protocol to categorize each pa-
tient’s substance use disorder.215 Information recorded at the initial screening
with the nurse or physician, toxicology results, and recommendations by the
substance use disorder professional are also considered.
After completing screening at the treatment center, a team of profes-
sionals, well-trained in treating substance use and behavioral health disor-
ders, shall compile an individualized recovery plan for each patient. All
patients, regardless of the level of recommended treatment, undergo MAT
dosed in accordance with standardized withdrawal assessments and the pro-
fessional opinions of the examiners.216 Buprenorphine, due to its milder fetal
214 A prototypical scenario where the substance use disorder professional may not recom-
mend treatment arises when a patient’s toxicology test indicates opioid use. Further evaluation
reveals no signs of abuse or dependence and the patient is taking an opioid, as prescribed, to
manage pain. The patient will not be referred to the specialized women’s treatment center, but
nevertheless will be monitored in subsequent prenatal visits to ensure the original non-abusive
assessment has not changed.
215 An example of such a standardized assessment that categorizes substance use disorder
is the Addiction Severity Index (ASI). The ASI is a semi-structured interview designed to
address seven potential problem areas in substance-abusing patients: medical status, employ-
ment and support, drug use, alcohol use, legal status, family/social status, and psychiatric sta-
tus. In one hour, a skilled interviewer can gather information on recent (past 30 days) and
lifetime problems in all of the problem areas. The ASI provides an overview of problems
related to substance, rather than focusing on any single area. NAT’L INST. ON DRUG ABUSE,
U.S. DEP’T OF HEALTH AND HUMAN SERVICES, ASSESSING ALCOHOL PROBLEMS: A GUIDE FOR
CLINICIANS AND RESEARCHERS 245 (2003), http://pubs.niaaa.nih. gov/publications/Assessin-
gAlcohol/InstrumentPDFs/04_ASI.pdf [https://perma.cc/NQ8X-39H5].
216 Examples of standardized withdrawal assessment are the Clinical Opiate Withdrawal
Scale (COWS) or Clinical Institute Narcotic Assessment Scale for Withdrawal Symptoms
(CINA). These tools measure signs and symptoms commonly seen in patients during opioid
withdrawal and aid clinicians in treatment-related decisions. By quantifying the severity of
withdrawal symptoms, clinicians are able to monitor treatment progress and develop evidence-
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effects and recently proven success rate, shall be the standard of care for
initiating MAT at the specialized women’s treatment centers.217 Patients cur-
rently on methadone maintenance plans shall continue with methadone;
however, dosages will be recalibrated and split throughout the day to best
protect the fetus from exposure to daily fluctuations.218 Individualized treat-
ment plans place patients in one of two treatment settings, both of which are
located in public hospitals to effectively serve treatment and prenatal needs.
Patients going into labor while attending opioid treatment services are trans-
ported to the maternal services unit of the hospital and receive care by that
unit’s doctors, nurses, and staff. Medication shall be administered as pre-
scribed through labor and delivery to avoid maternal and fetal withdrawal.
Moderate and severe misusers are placed in specialized residential
treatment facilities within public hospitals. Each residential treatment center
dispenses medication to patients as prescribed. During treatment, patients are
guided through the turbulent transition from a lifestyle marked by active
substance use disorder to one of recovery, health, and wellness. The length
of stay for patients in residential treatment is determined by several factors
including, but not limited to, severity of misuse as determined by standard-
ized tools, substance abuse history, criminal history, and existence of co-
occurring disorders or other mental health diagnoses. Recommendations by
residential treatment staff may also influence length of stay, however, pa-
tients will not, absent extraordinary circumstances, be permitted to stay in
residential treatment more than ninety days after admission.
An outpatient facility is located in the same hospital as the residential
treatment facility. Patients attending intensive outpatient treatment are pro-
vided medication as prescribed at the facility. A typical day of treatment
consists of extensive group therapy and individual counseling, with a
twelve-step recovery meeting to conclude each day. Essentially, the outpa-
tient treatment program trains patients to become proficient in key aspects of
recovery such as trigger219 avoidance, craving management, and successful
reintegration into society. A focal point of outpatient treatment seeks to en-
sure that before discharge all patients grasp the important principle that re-
covery is a lifelong journey—one requiring constant maintenance.
based data. See D.R. Wesson & W. Ling, The Clinical Opiate Withdrawal Scale (COWS),
35(2) J. PSYCHOACTIVE DRUGS 253, 253–59 (2003); see also J.E. Peachey & H. Lei, Assess-
ment of opioid dependence with naloxone, 83(2) BRITISH J. ADDICTION 193201 (1988).
217 See supra notes 103–109 and accompanying text.
218 Split dosing might be a preferable strategy for pregnant women maintained on metha-
done because it reduces fetal neurobehavioral effects without significantly altering maternal
physiological indicators. See generally, Lauren M. Jansson et al., Maternal Methadone Dosing
Schedule and Fetal Neurobehavior, 22(1) J. MATERN. FETAL NEONATAL MED. 29–35 (2009).
219 A trigger is an event that occurs before a person uses drugs or alcohol and increases the
likelihood of using. See ALAN J. BUDNEY & STEPHEN T. HIGGINS, NAT’L INST. ON DRUG
ABUSE, THERAPY MANUALS FOR DRUG ADDICTION, A COMMUNITY REINFORCEMENT AP-
PROACH: TREATING COCAINE ADDICTION 57 (1998), https://archives.drugabuse.gov/pdf/CRA
.pdf [https://perma.cc/8KXF-7YN3].
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The outpatient program targets two main groups of patients. One group
consists of patients who naturally progress to the intensive outpatient pro-
gram upon successful completion of residential treatment. Patients with re-
cently developed, less severe disorders, and patients who misuse opioids but
do not display withdrawal symptoms, are also assigned to this mode of treat-
ment. Treatment scheduling is determined on a case-by-case basis taking into
account factors such as employment, transportation, medical appointments,
and recommendations by referring providers. Random toxicology tests are
administered throughout intensive outpatient treatment; however, positive
screens are not grounds for dismissal.220 Outpatient treatment services will
be rendered for a length of time to be decided by staff and shall not exceed
six months from the date of patient admittance.
Discharge from intensive outpatient treatment marks completion of the
proposed model to prevent incidence of NAS through a facilitative system.
For the recovering misuser, however, the journey has just begun. Unlike the
congressional feud that resulted over President Obama’s proposal to allocate
$1.1 billion of mandatory funding to expand access to treatment for opioid
misuse,221 Massachusetts residents are urged to continue the initiative against
opioid misuse by collaboratively forming solutions to curb the epidemic.
The preventative system described above, if uniformly implemented
throughout the state, would successfully lower NAS rates sparing the epi-
demic’s most vulnerable and innocent victims substantial pain and suffering
while easing burdens on Massachusetts taxpayers. On a larger scale, state-
wide adoption of the system would successfully contribute to containing the
epidemic as a whole by lowering the rate of opioid use disorder among preg-
nant women through standardized, effective, and accessible treatment.
220 Although it is not a necessary part of recovery, relapse may be considered a normal
part of recovery. Many misusers require multiple attempts to achieve long-term recovery, often
learning valuable lessons from these setbacks and slips along the way. See Carol A. Shivley,
Relapse and Recovery in Addictions, 347 N. ENGL. J. MED. 225-26 (2002) (Substance abuse is
a chronic, relapsing disease — a view that allows relapse to be expected as a normal part of
recovery and that considers treatment successful if the disease is managed, not cured.). See see
also NAT’L INST. ON DRUG ABUSE, U.S. DEP’T OF HEALTH AND HUMAN SERVICES, PRINCIPLES
ON DRUG ADDICTION TREATMENT: A RESEARCH-BASED GUIDE 3 (2012) (Recovery from drug
addiction is a long-term process and frequently requires multiple episodes of treatment. As
with other chronic illnesses, relapses to drug abuse can occur and should signal a need for
treatment to be reinstated or adjusted.).
221 See The White House Office of the Press Secretary, Fact Sheet: President Obama
Proposes $I.I Billion in New Funding to Address the Prescription Opioid Abuse and Heroin
Use Epidemic, THE WHITE HOUSE: PRESIDENT BARACK OBAMA (Feb. 2, 2016), https://
obamawhitehouse.archives.gov/the-press-office/2016/02/02/president-obama-proposes-11-bil-
lion-new-funding-address-prescription [https://perma.cc/WP4G-CYJX]; see also Gardiner
Harris, Congress Splits Over Bill Aimed at Nation’s Opioid Epidemic, N.Y. TIMES (Jul. 6,
2016), https://www.nytimes.com/2016/07/07/us/politics/congress-to-hash-out-final-bill-aimed-
at-opioid-epidemic.html [https://perma.cc/ZHQ2-AGLX].
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VII. CONCLUSION
What originally appeared as a classic success story for stakeholders in
pharmaceutical companies has proven to be disastrous for society at large.
Effectively fulfilling the prophecy of President Nixon’s words in his 1971
message to Congress on substance use disorder, a socio-cultural phenome-
non has emerged from the convergence of two social factors. Specifically,
the introduction and mass production of OxyContin and other opioid pain
medications during a time of liberal prescription practices, accompanied by a
dramatic increase in production and distribution of potent heroin by drug
cartels, has crept into American homes and neighborhoods quietly, causing
mass destruction from within.
The nation is currently in the midst of an opioid epidemic, and Massa-
chusetts has been hit particularly hard. Governor Baker, a key driving force
behind Massachusetts’ efforts to combat the crisis, has taken an aggressive
stance on the issue that should be emulated. Meanwhile, state leaders from
various sectors and fields have joined forces to develop solutions to quell the
epidemic. Such bipartisan efforts in Massachusetts are laudable.
In addition to burying four opioid overdose victims per day, the Com-
monwealth is home to a high number of opioid-associated neonatal absti-
nence syndrome cases. NAS, the clinical disorder in newborns due to in
utero exposure to certain substances, causes infants to endure unnecessary,
and certainly involuntary, pain and discomfort. Moreover, infants diagnosed
with NAS require longer hospital stays and accumulate significant treat-
ment-related expenses while detoxifying from opioids. This Article has sug-
gested that Massachusetts policy and state lawmakers should consider
implementing a standardized protocol specifically aimed at reducing state-
wide incidence of NAS. The proposed system is grounded in a facilitative
approach—the government, mother, and child share the common objective
of promoting maternal and fetal health—that identifies opioid use during
pregnancy at the first prenatal appointment through a screening process and
toxicology test administered to all patients. Patients with responses reflect-
ing current opioid use or positive toxicology tests undergo further evaluation
by a substance abuse professional. The professional assesses such patients
and either refers them to a specialized women’s center for treatment or rec-
ommends follow-up assessments at all subsequent appointments.
The proposed model will not eradicate NAS entirely. Some patients
may refuse treatment. Others, despite valiant efforts to achieve and maintain
recovery, will be unable to overcome the severity of substance use disorder.
Others may comply with the system, achieve and maintain a state of recov-
ery, yet bear a child with methadone- or buprenorphine-induced NAS. How-
ever, the proposed facilitative preventative approach, if adopted uniformly
throughout the Commonwealth, ensures access to treatment for all pregnant
opioid misusers, and should lower statewide NAS rates and opioid depen-
dence among pregnant women in Massachusetts. Undertaking this plan ur-
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gently and thoughtfully should result in a vital, humane victory for
Massachusetts, allowing its citizens to shift the momentum against the
opioid epidemic.
